Mucormycosis is an invasive fungal disease caused by saprophytic molds and is characterized by a fulminant course and high mortality. Reported increase of disease cases and more frequent mucormy-cosis superinfections in COVID-19 patients are of a serious concern. Head and neck area is the most typical location of mucormycosis and often the first symptoms are eminent in oral cavity, therefore a dentist may be the first healthcare practitioner to recognize signs of this dangerous and potentially fatal disease. Urgent diagnosis and implementation of appropriate treatment are essential for the patient’s survival. The dentist’s participation in postoperative care is necessary and due to the destructive nature of radical surgical treatment, prosthetic rehabilitation is required to improve the patient’s function and quality of life. Furthermore the vigilance of dentists will also allow early recognition of frequent recur-rences of this insidious infection.

Intra-articular injections form a substantial element of the temporomandibular joint disorder (TMD) therapy. Given the role played by IL-1β in pathology, the use of autologous conditioned serum (ACS) is well-founded. Despite years of effective use in different locations, data regarding the intra-articular administration of ACS in TMD is scarce, and the strategy itself is not routinely applied. This study aims to provide preliminary evidence on the therapeutic efficacy of administering intra-articular ACS in treating TMD. Patients with TMD who received intra-articular ACS were included. More invasive co-interventions, such as arthroscopy, were excluded. Final searches were conducted on 17 June 2025, using five databases (ACM, BASE, DOAJ, PubMed, and SciELO). Risk of bias was evaluated using the RoB 2 tool. The results were tabulated. Only one study met the inclusion criteria. When compared to dextrose prolotherapy in internal TMD, ACS therapy resulted in greater improvement in mouth opening, pain, and joint-sound reduction. The small sample size, head-to-head design, and limited blinding suggest a highly cautious interpretation of the findings. ACS is a promising, but still experimental, therapeutic strategy addressing critical mechanisms in TMD. However, the currently available data is insufficient to confirm the effectiveness and safety of such an approach, and further high-quality studies are needed. This study received no funding. PROSPERO registration number: CRD420251069310.

The importance of local anaesthetics in dentistry cannot be overestimated. Being the most commonly used drugs in dental practice, these medicines are simply indispensable, as they allow for intra-operative and partly post-operative pain control in procedures performed. The injectable agents, currently employed in dentistry, belong, almost exclusively, to the amino-amide class. The paper focuses on articaine — a peculiar amino-amide local anaesthetic, which exhibits exceptional features distinguishing it from other drugs in the group and endearing it to dental practitioners all over the world, at the same time. The structure of the drug is presented and characteristics arising from its unique attributes are discussed. The article covers the practical aspects of articaine use in various fields of dentistry and oral surgery and arising prospects for the future. Despite the wide safety margin of the agent, articaine, like any other local anaesthetic, may induce unwanted side-effects, which were also described here, and their management was briefly presented.

Pain is common in dental practice. It is not only a reason for patients seeking dental treatment, but it can also accompany performed procedures and often occurs after them. The management of acute pain consists of causative treatment and pharmacotherapy, with non-steroidal anti-inflammatory drugs (NSAIDs) being the drugs of choice in routine dental practice. These agents, however, may not be potent enough in cases with, pain of greater intensity. This paper focuses on tramadol, an atypical opioid, which is the most popular analgesic of this type in the world and can be considered a valuable option for the management of moderate to severe pain in dentistry and oral surgery. The characteristics of the agent were described, as well as its singular mechanism of action and biotransformation. Adverse effects that can occur during tramadol pharmacotherapy were discussed together with interactions significant in clinical practice. The available tramadol formulations were presented, with particular attention to the drug combinations examined in pain management in a dental setting.

Inhalation is one of the routes of drug administration used in therapy. Medicines are dispersed via an aerosol spray, mist, powder or vapour that patients breathe into their airways. Depending on the intrapulmonary behaviour of each molecule of the inhaled agent, the prevailing effect obtained may be local or general. Inhaled therapy, due to its local effect, is a cornerstone of obstructive pulmonary diseases like asthma and chronic obstructive pulmonary disease (COPD), while the general effects of vaporised medical cannabis support its use in other indications (e.g. epilepsy, insomnia, spastic pain). Regardless of the purpose of use, an inhaled drug passes through the oropharynx and a major portion of its dose remains there. This paper focuses on the impact of inhaled therapy on the oral cavity, highlighting the issues important for dental practitioners. The most common indications for inhaled therapy are presented together with the devices used for this route of administration and the drugs employed in outpatient care. Particular attention is paid to oral side effects of inhaled medicines and their pathophysiology. The advisable measures for dental care of patients using inhaled therapy are presented.

Tramadol is the most widely used analgesic in the world. Indications for the general administration of tramadol in dentistry and oral surgery are restricted to cases with moderate to severe pain. However, new evidence supports the peripheral use of this well-known drug. The unique properties of this atypical opioid, including its impact on neuronal conduction, attenuation of inflammation, and antimicrobial effects, together with its possible beneficial influence on the wound healing process, have been observed after local administration in human and animal research. The paper focuses on the local administration of tramadol within orofacial tissues, with particular consideration given to its possible use in dentistry.